Maintenance therapy with regorafenib (REGO) versus placebo after first-line (1L) platinum and fluoropyrimidinesbased chemotherapy in HER2-negative advanced gastric (GC)/gastroesophageal junction (GEJ) cancer: Results of phase II randomized a-MANTRA study (GOIRC-05-2016)

被引：0
|
作者：
Damato, A. [1 ]
Bilancia, D. [2 ]
Iachetta, F. [1 ]
Strippoli, A. [3 ]
Filiali, F. [4 ]
Casaretti, R. [5 ]
Bernardini, I. [6 ]
Bellotti, G. [7 ]
Frassineti, G. L. [8 ]
Di Fabio, F. [9 ]
Aieta, M. [10 ]
Ghidini, M. [11 ]
Trentin, C. [12 ]
Cardellino, G. [13 ]
Gervasi, E. [1 ]
Romagnani, A. [1 ]
Cinieri, S. [14 ]
Normanno, N. [15 ]
Boni, L. [16 ]
Pinto, C. [1 ]
机构：
[1] Azienda USL IRCCS Reggio Emilia, Ctr Comprehens Canc, Oncol & Tecnol Avanzate, Med Oncol, Reggio Emilia, Italy
[2] Az Osped San Carlo, Oncol, Potenza, Italy
[3] Fdn Policlin Univ Agostino Gemelli IRCCS, Oncol, Rome, Italy
[4] ASST Brianza, Vimercate Hosp, Oncol, Vimercate, Italy
[5] Ist Nazl Tumori IRCCS Fdn G Pascale, Expt Clin Abdominal Oncol Unit, Naples, Italy
[6] Osped Ramazzini, Oncol, Carpi, Italy
[7] Azienda Osped SS Antonio & Biagio & Cesare Arrigo, Oncol Unit, Oncol, Alessandria, Italy
[8] IRST Ist Romagnolo Tumori Dino Amadori IRCCS Srl, Oncol, Meldola, Italy
[9] AOU Policlin S Orsola Malpighi, Oncol, Bologna, Italy
[10] IRCCS CROB, Oncol Unit, Rionero In Vulture, Italy
[11] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Day Hosp Oncol, Milan, Italy
[12] Osped Santa Chiara APSS, Dept Med Oncol, Trento, Italy
[13] Azienda Sanitaria Univ Friuli Centrale, Oncol, Udine, Italy
[14] Osped A Perrino, Dept Med Oncol, Brindisi, Italy
[15] Ist Nazl Tumori IRCCS Fdn G Pascale, Translat Res Dept, Naples, Italy
[16] IRCCS Osped Policlin San Martino, Clin Epidemiol Unit, Genoa, Italy
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.335
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
421P
引用
收藏
页码：S171 / S171
页数：1
相关论文
共 50 条
  • [1] Phase II randomized study of maintenance therapy with regorafenib (REGO) versus placebo after first-line platinum and fluoropyrimidines-based chemotherapy in HER2 negative locally advanced/metastatic gastric (GC) or gastroesophageal junction (GEJ) cancer: Results of a-MANTRA study (GOIRC-05-2016)
    Damato, Angela
    Bilancia, Domenico
    Iachetta, Francesco
    Strippoli, Antonia
    Filiali, Francesca
    Casaretti, Rossana
    Bernardini, Ilaria
    Bellotti, Giovanna
    Frassineti, Giovanni Luca
    Di Fabio, Francesca
    Aieta, Michele
    Ghidini, Michele
    Trentin, Chiara
    Cardellino, Giovanni Gerardo
    Gervasi, Erika
    Romagnani, Alessandra
    Cinieri, Saverio
    Normanno, Nicola
    Pinto, Carmine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
    Rha, S. Y.
    Wyrwicz, L. S.
    Weber, P. E. Y.
    Bai, Y.
    Ryu, M. H.
    Lee, J.
    Rivera, F.
    Alves, G. V.
    Garrido, M.
    Shiu, K. -k.
    Fernandez, M. Gonzalez
    Li, J.
    Lowery, M.
    Cil, T.
    Cruz, F. J. S. M.
    Qin, S.
    Yin, L.
    Bordia, S.
    Bhagia, P.
    Oh, D-y.
    ANNALS OF ONCOLOGY, 2023, 34 (03) : 319 - 320
  • [3] Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2-advanced gastric or gastroesophageal junction cancer (GC/GEJC)
    Moehler, Markus H.
    Dvorkin, Mikhail
    Ozguroglu, Mustafa
    Ryu, Min-hee
    Muntean, Alina Simona
    Lonardi, Sara
    Nechaeva, Marina
    Bragagnoli, Arinilda Silva Campos
    Coskun, Hasan Senol
    Gracian, Antonio Cubillo
    Takano, Toshimi
    Wong, Rachel
    Safran, Howard
    Vaccaro, Gina M.
    Boku, Narikazu
    Conti, Ilaria
    Hong, Janet
    Xiong, Huiling
    Taieb, Julien
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [4] A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
    Qin, S.
    Tabernero, J.
    van Cutsem, E.
    Fuchs, C. S.
    Janjigian, Y. Y.
    Bhagia, P.
    Li, K.
    Adelberg, D.
    Bang, Y-J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1316 - S1317
  • [5] Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
    Moehler, Markus H.
    Kato, Ken
    Arkenau, Hendrik-Tobias
    Oh, Do-Youn
    Tabernero, Josep
    Cruz-Correa, Marcia
    Wang, HongWei
    Xu, Hui
    Li, Jiang
    Yang, Silu
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 286 - 286
  • [6] Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results
    Ciardiello, Fortunato
    Bang, Yung-Jue
    Cervantes, Andres
    Dvorkin, Mikhail
    Lopez, Charles D.
    Metges, Jean-Philippe
    Sanchez Ruiz, Antonio
    Calvo, Mariona
    Strickland, Andrew H.
    Kannourakis, George
    Muro, Kei
    Kawakami, Hisato
    Wei, Jia
    Borg, Christophe
    Zhu, Zhaoyin
    Gupta, Neal
    Pelham, Robert J.
    Shen, Lin
    CANCER MEDICINE, 2023, 12 (12): : 13145 - 13154
  • [7] Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study
    Lee, K-W.
    Bai, L-Y.
    Jung, M.
    Ying, J.
    Im, Y-H.
    Oh, D-Y.
    Cho, J. Y.
    Oh, S. C.
    Chao, Y.
    Zhou, P.
    Bao, Y.
    Kang, Y-K.
    ANNALS OF ONCOLOGY, 2023, 34 : S855 - S856
  • [8] Health-related quality of life (hrqol) analysis from KEYNOTE-859: First-line (1L) pembrolizumab (pembro) plus chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Lowery, M.
    Wyrwicz, L.
    Oh, D-Y.
    Shiu, K. K.
    Weber, P. Yanez
    Bai, Y.
    Lee, J.
    Rivera, F.
    Alves, G.
    Garrido, M.
    Fernandez, M. Gonzalez
    Li, J.
    Cil, T.
    Cruz, F.
    Qin, S.
    Yin, L.
    Valderrama, A.
    Bordia, S.
    Rha, S. Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S854 - S855
  • [9] Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
    Moehler, M.
    Shitara, K.
    Garrido, M.
    Salman, P.
    Shen, L.
    Wyrwicz, L.
    Yamaguchi, K.
    Skoczylas, T.
    Campos Bragagnoli, A.
    Liu, T.
    Schenker, M.
    Yanez, P.
    Tehfe, M.
    Poulart, V.
    Cullen, D.
    Lei, M.
    Kondo, K.
    Li, M.
    Ajani, J. A.
    Janjigian, Y. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1191 - S1191
  • [10] JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).
    Moehler, Markus H.
    Ryu, Min-Hee
    Lee, Keun-Wook
    Coskun, Hasan Senol
    Wong, Rachel
    Ozguroglu, Mustafa
    Chung, Hyun-Choel
    Poltoratsky, Artem
    Tsuji, Akihito
    Yen, Chia-Jui
    Muntean, Alina
    le Sourd, Samuel
    Vaccaro, Gina M.
    Taieb, Julien
    Boku, Narikazu
    Sharma, Maitreyi
    Xiong, Huiling
    Conti, Ilaria
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345